Abstract
Excess death rates E during the spring of 2020 are computed in N = 340 level 3 European territorial units for statistics —NUTS3 in Netherlands (44), Belgium (40), France (96), Spain (50) and Italy (110)— from 2020 provisional week deaths, the population numbers for 2020, and observations in previous years (reference or baseline), all of them obtained from Eurostat web page.
The distribution of excess death rates is found to follow an exponential law with empirical complementary cumulative distribution function Y following log Y = a + b(E − ⟨ E⟩) /s. In the middle of the distribution b1 = −1.356(9); R2 = 0.998 are found and for the largest 46 excess death rates b1 = −0.645(18); R2 = 0.992 is observed. This result suggests that abnormally large excess death rates may develop in statistical regions independently of what happens in the outside.
Distribution of excess death rates are also analyzed on a country basis. A two-sample Kolmogorov-Smirnov test does not reject the null hypothesis “normal values of E for country i and country j come from the same parent distribution” for any pairing. This is an evidence of a common background in the outcomes. In other words statistical differences among countries can be characterized by averages and standard deviations only. Average death rates, sample standard deviations, excess death tolls are: Netherlands 407 × 10−6, 387 × 10−6, 8104; Belgium 667× 10−6, 364 ×10−6, 8436; France 228 × 10−6, 377 × 10−6, 21 780 (overseas departments not included); Spain 1059 × 10−6, 1149 × 10−6, 48 931 (Canary Islands not included); Italy 791 × 10−6, 1140 × 10−6, 49 184; and 610 ×10−6, 877 × 10−6, 136 435 for the combined distribution. A Kolmogorov-Smirnov test rejects (p < 0.001) the null hypothesis “normal scores of E come from a Gaussian distribution” only for Italian data and the whole set of excess death rates.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No founding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not needed.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam.